Chris Larkins

Chris joined the CSL Seqirus business in 2015 and his most recent role was Global Head of Manufacturing responsible for CSL Seqirus’ 3 facilities in Parkville, Holly Springs and Liverpool. Chris has over 26 years’ experience in the pharmaceutical industry across a range of Operations, Quality and Supply Chain roles specialising in vaccines, biologics and sterile manufacturing. In 2001 Chris joined Schering-Plough Ltd. in Singapore as Head of Production to build, commission and gain FDA approval of a new sterile manufacturing plant. He was later promoted to Director of Operations and oversaw the successful qualification of new biologics for hepatitis C and rheumatoid arthritis. In 2007 Chris relocated to Lucerne, Switzerland as Head of Quality and QP at Schering’s Biologics facility producing a range of clinical Biologic Drug Substances and Clinical Supplies. Following the merger with Merck & Co. Chris relocated to Pennsylvania, U.S to manage Global Quality across 5 sites in Europe and the United States. This included the successful launch in 2014 of the first PD-1 inhibitor for cancer immunotherapy. Chris holds a B.Eng. (Chem) from the University of Melbourne and an M.B.A. from the Chicago Booth School of Business.